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Purpose
Lipoic acid (LA) stimulates production of an immuno-
modulatory molecule, cAMP, that may have therapeutic
benefit in multiple sclerosis (MS). The study sought to
determine the bioactivity of two forms of oral LA, race-
mic (R/S-LA) and R-LA, to identify factors that may
improve the therapeutic effectiveness of LA in MS.
Methods
Participants met the following criteria: age 18-70 years and
a definite multiple sclerosis diagnosis. Consenting partici-
pants were randomized to 2 groups: R/S-LA (n=20) or
R-LA (n=8). Blood was collected at baseline, 5, 10, 15, 30,
60, 90, 120, 180, 240, and 300 minutes after ingestion of a
single 1200 mg LA dose. Bioactivity was determined by
measuring immune cell cAMP levels (pmol/mg) at base-
line and 240 minutes post ingestion. Group differences
were analyzed by repeated measures analysis of variance
(cAMP) and t-test (pharmacokinetics).
Results
For R/S-LA, mean baseline cAMP levels were 8.6 (SE
0.83) pmol/mg protein, which increased to 14.1 (SE 1.7)
240 minutes post-ingestion. For R-LA, baseline cAMP
levels were 5.7 (SE 0.54), which decreased to 4.7 (SE
0.41) 240 minutes post-ingestion. The mean change in
cAMP levels were different between groups, p<0.01. The
two groups showed no differences in serum LA levels at
240 minutes (p=0.29), but showed a difference in the
mean AUC (min*mcg/ml): R/S-LA is 681.8 (SE 83.4) and
R-LA is 389.5 (SE 43.9) (p<0.01). Tmax (minutes)
between groups differed: R/S-LA was 81.0 (SE 8.9) and
R-LA was 13.1 (SE 2.7); p<0.001.
Conclusion
At 1200 mg oral dose and comparable serum LA levels
at T240, R/S-LA showed higher cAMP levels compared
to R-LA. Since R-LA had an earlier Tmax, it is plausible
that increases in cAMP may have occurred at earlier
undetected time-points. This pilot study warrants
further investigation as differences between R-LA and
R/S-LA in bioactivity and pharmacokinetics would
impact clinical trial design and patient care.
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